Kaye, A.D.; Ford, B.M.; Abbott, B.M.; Broocks, K.M.; Novacic, S.; Shekoohi, S.
Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease. Diseases 2025, 13, 290.
https://doi.org/10.3390/diseases13090290
AMA Style
Kaye AD, Ford BM, Abbott BM, Broocks KM, Novacic S, Shekoohi S.
Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease. Diseases. 2025; 13(9):290.
https://doi.org/10.3390/diseases13090290
Chicago/Turabian Style
Kaye, Alan D., Bennett M. Ford, Brennan M. Abbott, Kalob M. Broocks, Sofia Novacic, and Sahar Shekoohi.
2025. "Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease" Diseases 13, no. 9: 290.
https://doi.org/10.3390/diseases13090290
APA Style
Kaye, A. D., Ford, B. M., Abbott, B. M., Broocks, K. M., Novacic, S., & Shekoohi, S.
(2025). Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease. Diseases, 13(9), 290.
https://doi.org/10.3390/diseases13090290